Staff Publications

Staff Publications

  • external user (warningwarning)
  • Log in as
  • language uk
  • About

    'Staff publications' is the digital repository of Wageningen University & Research

    'Staff publications' contains references to publications authored by Wageningen University staff from 1976 onward.

    Publications authored by the staff of the Research Institutes are available from 1995 onwards.

    Full text documents are added when available. The database is updated daily and currently holds about 240,000 items, of which 72,000 in open access.

    We have a manual that explains all the features 

Record number 347093
Title A novel recombinant virus-like particle vaccine for prevention of porcine parvovirus-induced reproductive failure
Author(s) Antonis, A.F.G.; Bruschke, C.J.M.; Rueda, P.; Maranga, L.; Casal, J.; Vela, C.; Hilgers, L.A.T.; Belt, P.B.G.M.; Weerdmeester, K.; Carrondo, M.J.; Langeveld, J.P.M.
Source Vaccine 24 (2006)26. - ISSN 0264-410X - p. 5481 - 5490.
DOI https://doi.org/10.1016/j.vaccine.2006.03.089
Department(s) ASG Infectieziekten
ID - Infectieziekten
ASG Strategie & Control
ASG ProductenProducten
CIDC - Divisie Bacteriologie en TSE's
Publication type Refereed Article in a scientific journal
Publication year 2006
Keyword(s) immune-responses - experimental-infection - baculovirus vectors - canine parvovirus - pregnant gilts - disease - pigs - coinfection - volunteers - adjuvants
Abstract A novel vaccine against porcine parvovirus (PPV), composed of recombinant virus-like particles (PPV-VLPs) produced with the baculovirus expression vector system (BEVS) at industrial scale, was tested for its immunogenicity and protective potency. A formulation of submicrogram amounts of PPV-VLPs in a water-in-mineral oil adjuvant evoked high serum antibody titres in both guinea pigs, used as reference model, and target species, pigs. A single immunisation with 0.7 ¿g of this antigen yielded complete foetal protection against PPV infection after challenge with a virulent strain of this virus. Furthermore, also in the presence of mild adjuvants the protective action of these PPV-VLPs is excellent. This recombinant subunit vaccine overcomes some of the drawbacks of classical PPV vaccines
Comments
There are no comments yet. You can post the first one!
Post a comment
 
Please log in to use this service. Login as Wageningen University & Research user or guest user in upper right hand corner of this page.